


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. - 139. (Cancelled)

~~A 1~~ 140. (Previously presented) A taxoid of the formula




in which

R represents hydrogen or acetyl,

R₁ represents benzoyl or R₂-O-CO- in which R₂ represents t-butyl, and

Ar represents phenyl or α- or β-naphthyl, said phenyl or naphthyl being unsubstituted or substituted by C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, or CF₃, or Ar represents 2- or 3-thienyl or 2- or 3-furyl, said thienyl or furyl being unsubstituted or substituted by halogen.

141. (Previously presented) A taxoid of the formula:




in which G_1 represents hydrogen or acetyl.

142. (Previously presented) 4 α -10 β -diacetoxo-2 α -benzoyloxy-5 β ,20-epoxy-1 β -hydroxy-7 β ,8 β -methylene-9-oxo-19-nor-11-taxen-13 α -yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate.

F 1
cont

143. (New) A method of treating breast cancer comprising administering to a human having breast cancer, an effective amount of a taxoid of formula (I)



in which

R represents hydrogen or acetyl,


R_1 represents benzoyl or R_2 -O-CO- in which R_2 represents t-butyl, and

Ar represents phenyl or α - or β -naphthyl, said phenyl or naphthyl being unsubstituted or substituted by C_{1-4} alkyl, C_{1-4} alkoxy, halogen, or CF_3 , or Ar represents 2- or 3-thienyl or 2- or 3-furyl, said thienyl or furyl being unsubstituted or substituted by halogen.

144. (New) A method of treating breast cancer comprising administering to a human having breast cancer, an effective amount of 4 α -10 β -diacetoxo-2 α -benzoyloxy-5 β ,20-

epoxy-1 β -hydroxy-7 β ,8 β -methylene-9-oxo-19-nor-11-taxen-13 α -yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate.

145. (New) A method of treating ovarian cancer comprising administering to a human having ovarian cancer, an effective amount of a taxoid of formula (I)



in which


R represents hydrogen or acetyl,

R₁ represents benzoyl or R₂-O-CO- in which R₂ represents t-butyl, and

Ar represents phenyl or α - or β -naphthyl, said phenyl or naphthyl being unsubstituted or substituted by C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, or CF₃, or Ar represents 2- or 3-thienyl or 2- or 3-furyl, said thienyl or furyl being unsubstituted or substituted by halogen.

146. (New) A method of treating ovarian cancer comprising administering to a human having ovarian cancer, an effective amount of 4 α -10 β -diacetoxo-2 α -benzoyloxy-5 β ,20-epoxy-1 β -hydroxy-7 β ,8 β -methylene-9-oxo-19-nor-11-taxen-13 α -yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate.

147. (New) A method of treating melanoma comprising administering to a human having melanoma, an effective amount of a taxoid of formula (I)



in which


R represents hydrogen or acetyl,

R₁ represents benzoyl or R₂-O-CO- in which R₂ represents t-butyl, and

Ar represents phenyl or α - or β -naphthyl, said phenyl or naphthyl being unsubstituted or substituted by C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, or CF₃, or Ar represents 2- or 3-thienyl or 2- or 3-furyl, said thienyl or furyl being unsubstituted or substituted by halogen.

148. (New) A method of treating melanoma comprising administering to a human having melanoma, an effective amount of 4 α -10 β -diacetoxo-2 α -benzoyloxy-5 β ,20-epoxy-1 β -hydroxy-7 β ,8 β -methylene-9-oxo-19-nor-11-taxen-13 α -yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate.

149. (New) A method of treating colon cancer comprising administering to a human having colon cancer, an effective amount of a taxoid of formula (I)



FI
Carl
in which


R represents hydrogen or acetyl,

R₁ represents benzoyl or R₂-O-CO- in which R₂ represents t-butyl, and

Ar represents phenyl or α- or β-naphthyl, said phenyl or naphthyl being unsubstituted or substituted by C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, or CF₃, or Ar represents 2- or 3-thienyl or 2- or 3-furyl, said thienyl or furyl being unsubstituted or substituted by halogen.

150. (New) A method of treating colon cancer comprising administering to a human having colon cancer, an effective amount of 4α-10β-diacetoxy-2α-benzoyloxy-5β,20-epoxy-1β-hydroxy-7β,8β-methylene-9-oxo-19-nor-11-taxen-13α-yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate.

151. (New) A method of treating pancreatic cancer comprising administering to a human having pancreatic cancer, an effective amount of a taxoid of formula (I)



in which

R represents hydrogen or acetyl,


R₁ represents benzoyl or R₂-O-CO- in which R₂ represents t-butyl, and

Ar represents phenyl or α - or β -naphthyl, said phenyl or naphthyl being unsubstituted or substituted by C₁₋₄ alkyl, C₁₋₄ alkoxy, halogen, or CF₃, or Ar represents 2- or 3-thienyl or 2- or 3-furyl, said thienyl or furyl being unsubstituted or substituted by halogen.

F1
cont

152. (New) A method of treating pancreatic cancer comprising administering to a human having pancreatic cancer, an effective amount of 4 α -10 β -diacetoxo-2 α -benzoyloxy-5 β ,20-epoxy-1 β -hydroxy-7 β ,8 β -methylene-9-oxo-19-nor-11-taxen-13 α -yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate.

153. (New) A method of treating leukemia comprising administering to a human having leukemia, an effective amount of a taxoid of formula (I)



in which

R represents hydrogen or acetyl,

R₁ represents benzoyl or R₂-O-CO- in which R₂ represents t-butyl, and

Ar represents phenyl or α - or β -naphthyl, said phenyl or naphthyl being unsubstituted or substituted by C_{1-4} alkyl, C_{1-4} alkoxy, halogen, or CF_3 , or Ar represents 2- or 3-thienyl or 2- or 3-furyl, said thienyl or furyl being unsubstituted or substituted by halogen.

F1
Cat

154. (New) A method of treating leukemia comprising administering to a human having leukemia, an effective amount of 4 α -10 β -diacetoxy-2 α -benzoyloxy-5 β ,20-epoxy-1 β -hydroxy-7 β ,8 β -methylene-9-oxo-19-nor-11-taxen-13 α -yl (2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate.
